Tirzepatide shots: what actually happens from first pen to steady routine

Step 1 — your first pen and the adjustment phase

The treatment opens with the 2.5 mg pen. Its job is to acclimatise your system, not yet to drive significant weight loss, so it is worth adjusting your expectations for those first four weeks. Most people notice some nausea or stomach discomfort, particularly in the days after each injection; this typically settles as the body adapts. Injection sites rotate between the abdomen, thigh and upper arm, and the KwikPen format means no drawing up of liquid and no exposed needle to manage. You inject once a week, on the same day each week where possible, and our Mounjaro shots page explains how each injection works in practice, including what to expect before, during and after you use the pen. Some people find it easiest to tie it to a low-key anchor, such as the first Monday after payday, a day off, or a fixed slot before work. If you'd like to understand the broader picture of how tirzepatide works physiologically, the tirzepatide overview page covers the mechanism in more depth. The NHS also explains the medicine's effects and common reactions in plain language at its tirzepatide medicines page.

Step 2 — dose titration and what your prescriber is watching for

After four weeks at 2.5 mg, most people move to 5 mg, then upward in approximately four-week steps if the previous dose is well tolerated. The ceiling is 15 mg, though not everyone needs or reaches it. Your prescriber isn't following a conveyor belt: the pace depends on how your body is responding, whether side effects are manageable, and what your weight trajectory looks like. Gastrointestinal symptoms (nausea, loose stools, reduced appetite, occasional vomiting) are the most commonly reported reactions and are usually most noticeable in the first couple of days after each dose increase. They rarely persist at the same intensity once you've settled at a given level. There is one detail worth raising with your prescriber if you take an oral contraceptive pill: for the first four weeks of treatment and for four weeks after each dose increase, an additional non-oral method of contraception is advisable because tirzepatide's effect on gastric emptying may reduce pill absorption. This is a specific interaction documented in NHS guidance. Separately, tell your surgical team and anaesthetist if you're due any procedure while on treatment. Our Mounjaro information page covers these practical points in further detail.

Step 3, life at maintenance dose and what the evidence shows

Once you reach a dose that suits you, the rhythm becomes genuinely routine: one injection a week, kept refrigerated between 2–8 °C, and always accompanied by the reduced-calorie diet and increased activity that the licence requires. The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported approximately 20–21% average body-weight reduction at 15 mg over 72 weeks in a population of thousands of adults with obesity. That is a trial result with lifestyle support alongside it, not a guarantee for any individual. The subsequent SURMOUNT programme data across other populations added further detail on who benefits most. If you're weighing the cost of longer-term private treatment, the Mounjaro price comparison page sets out what the UK private market looks like and what should realistically be included in any quoted price. Whether tirzepatide shots are right for you is not a decision made by a checklist: it requires a prescriber who can look at your full health picture.

What happens if a shot is missed or a dose question comes up

Missed doses, timing queries and questions about pen storage windows all belong with your prescriber and the Patient Information Leaflet, not a general content page. That is not a deflection; it reflects the fact that individual circumstances vary significantly. If a severe, persistent abdominal pain develops, especially pain that spreads toward the back with or without vomiting, seek medical help promptly, as this may indicate pancreatitis, a known, if infrequent, risk the MHRA has specifically highlighted for GLP-1 medicines. A common concern that does come up is whether taking two Mounjaro shots is ever appropriate, and that page explains clearly why doubling up is not recommended and what to do instead. Any suspected side effect, or concern about the pen you've received, can be logged at the MHRA's Yellow Card scheme. For questions specific to your treatment, our aftercare team is available seven days a week. And if you're still exploring what weight-loss treatment might suit you more broadly, the weight-loss treatment overview is a good place to start before speaking to a prescriber. When you're ready to take the next step, checking your eligibility through a free consultation is straightforward and carries no obligation.